RecruitingNot applicableNCT03174938

The Swedish BioFINDER 2 Study

Studying Atypical progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Skane University Hospital
Principal Investigator
Oskar Hansson, MD, Professor
Skåne University Hospital, and Lund University
Intervention
Flutemetamol F18 Injection(diagnostic_test)
Enrollment
2950 enrolled
Eligibility
20-100 years · All sexes
Timeline
20172028

Study locations (2)

Collaborators

Lund University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03174938 on ClinicalTrials.gov

Other trials for Atypical progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Atypical progressive supranuclear palsy syndrome

← Back to all trials